【重要更新】CDC更新官方手册，武汉生物、康希诺和三叶草新冠疫苗符合要求了？

刚刚看到北美票帝的公众号更新，立刻去翻CDC的官方文件，发现更新内容中多了一项“Participants in Certain COVID-19 Vaccine Trials”的内容（附件1），其中将接种康希诺（CanSinoBIO）、国药武汉生物WIBP（Sinopharm/WIBP）和三叶草（Clover Biopharmaceuticals）三类疫苗三期测试的接种者视为符合豁免要求，凭相关证明可进入美国。

我个人理解和票帝分析一致，只要正常接种过上述三种疫苗（非安慰剂，不过应该正常接种的没有安慰剂吧？）的都应该视作fully vaccinated，欢迎大家留言讨论，最近一直在关注这个疫苗的新政，有其他问题的小伙伴也可以一起讨论。

【此贴长期更新。。。】

附1:CDC的官方说明

Participants in Certain COVID-19 Vaccine Trials
Airlines and airline operators must confirm that any Covered Individual claiming this exception has official documentation (e.g., clinical trial letter, participant card, or modified vaccination card) of clinical trial participation that includes the following information:
- Passenger has participated or is participating in a Phase 3 COVID-19 vaccine trial with a qualifying vaccine candidate listed in Table 3 below that meets CDC criteria for the exception; AND
- Passenger received the full series of an active (non-placebo) COVID-19 qualifying vaccine candidate, and lists name of the vaccine product and the date(s) received. See table 3 for the list of COVID-19 qualifying vaccine candidates.
If a passenger received the full series of an accepted COVID-19 vaccine (non-placebo) in a clinical trial, the passenger is considered fully vaccinated. See table 2 for the list of accepted COVID-19 vaccines.
Airlines and airline operators must review the information presented by the passenger to ensure that:
- Personal identifiers in the clinical trial documentation (full name plus at least one other identifier such as date of birth or passport number) match with the passenger’s passport or other travel documentation;
- The name of the COVID-19 vaccine product the participant received matches with a vaccine product listed in Table 3; AND
- Vaccine series was completed at least 2 weeks (14 days) before the flight’s departure.
Airlines or aircraft operators must also confirm that the passenger has provided an Excepted Covered Individual Attestation.

附2: 更新的三种疫苗
附3: WHO的EUL审批进度表
extranet.who.int